Blood Reviews
Volume 21, Issue 4 , Pages 201-216 , July 2007

Peripheral T-cell Lymphomas

References 

  1. Jaffe ES, Harris NL, Stein H, Vardiman J. In:  Jaffe ES,  Harris NL,  Stein H,  Vardiman JW editor. World Health Organization Classification: Tumours of Hematopoetic and lymphoid Tissues. Lyon: IARC Prsss; 2001;
  2. Savage KJ. Aggressive peripheral T-cell lymphomas (specified and unspecified types). Hematology Am Soc Hematol Educ Program. 2005;267–277
  3. Kwak LW, Wilson M, Weiss LM, Doggett R, Dorfman RF, Warnke RA, et al. Similar outcome of treatment of B-cell and T-cell diffuse large-cell lymphomas: the Stanford experience. J Clin Oncol. 1991;9(8):1426–1431
  4. Melnyk A, Rodriguez A, Pugh WC, Cabannillas F. Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin’s lymphoma. Blood. 1997;89(12):4514–4520
  5. Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Briere J, Haioun C, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin’s lymphomas. Groupe d’Etudes des Lymphomes de l’Adulte (GELA). Blood. 1998;92(1):76–82
  6. Morabito F, Gallamini A, Stelitano C, Callea V, Guglielmi C, Neri S, et al. Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linformi. Cancer. 2004;101(7):1601–1608Oct 1
  7. Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004;15(10):1467–1475Oct
  8. Lopez-Guillermo A, Cid J, Salar A, Lopez A, Montalban C, Castrillo JM, et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Annals of Oncology. 1998;9(8):849–855
  9. Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2003;(Nov 26):
  10. Mason DY, Bastard C, Rimokh R, Dastugue N, Huret JL, Kristoffersson U, et al. CD30-positive large cell lymphomas (’Ki-1 lymphoma’) are associated with a chromosomal translocation involving 5q35. see comments Br J Haematol. 1990;74(2):161–168
  11. Banks PM, Warnke RA. Mature T-cell and NK-cell neoplasms. In:  Jaffe ES,  Harris NL,  Stein H,  Vardiman JW editor. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Hematopoetic and lymphoid Tissues. Lyon: IARC Prsss; 2001;p. 189–230
  12. Nascimento AF, Pinkus JL, Pinkus GS. Clusterin, a marker for anaplastic large cell lymphoma immunohistochemical profile in hematopoietic and nonhematopoietic malignant neoplasms. Am J Clin Pathol. 2004;121(5):709–717May
  13. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood. 1997;89(11):3909–18.
  14. Morris SW, Kirstein MN, Valentine MB, Dittmer K, Shapiro DN, Look AT, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non- Hodgkin’s lymphoma [letter]. Science. 1995;267(5196):316–317
  15. ten Berge RL, Oudejans JJ, Ossenkoppele GJ, Pulford K, Willemze R, Falini B, et al. ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination. see comments J Clin Pathol. 2000;53(6):445–450
  16. Gascoyne RD, Aoun P, Wu D, Chhanabhai M, Skinnider BF, Greiner TC, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood. 1999;93(11):3913–3921
  17. Falini B, Pileri S, Zinzani PL, Carbone A, Zagonel V, Wolf-Peeters C, et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood. 1999;93(8):2697–2706
  18. Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia. 2005;19(12):2186–2194Dec
  19. Attygalle A, Al-Jehani R, Diss TC, Munson P, Liu H, Du MQ, et al. Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood. 2002;99(2):627–633Jan 15
  20. Dupuis J, Boye K, Martin N, Copie-Bergman C, Plonquet A, Fabiani B, et al. Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol. 2006;30(4):490–494Apr
  21. Grogg KL, Attygale AD, Macon WR, Remstein ED, Kurtin PJ, Dogan A. Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified. Mod Pathol. 2006;19(8):1101–1107Aug
  22. Dogan A, Attygalle AD, Kyriakou C. Angioimmunoblastic T-cell lymphoma. Br J Haematol. 2003;121(5):681–691Jun
  23. Jaffe ES, Railfkiaer E. Mature T-cell and NK neoplasms: Introduction. In:  Jaffe ES,  Harris NL,  Stein H,  Vardiman JW editor. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Hematopoetic and lymphoid Tissues. Lyon: IARC Press; 2001;p. 191–194
  24. Belhadj K, Reyes F, Farcet JP, Tilly H, Bastard C, Angonin R, et al. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood. 2003;102(13):4261–4269Dec 15
  25. Toro JR, Liewehr DJ, Pabby N, Sorbara L, Raffeld M, Steinberg SM, et al. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood. 2003;101(9):3407–3412May 1
  26. Wang H, Medeiros LJ, Jones D. Subcutaneous panniculitis-like T-cell lymphoma. Clin Lymphoma. 2002;3(3):181–183Dec
  27. Shipp M, Harrington D, Chairpersons , Anderson J, Armitage J, Bonadonna G, et al. A predictive model for aggressive non-Hodgkin’s lymphoma: The International NHL Prognostic Factors Project. N Engl J Med. 1993;329:987–994
  28. ten Berge RL, Oudejans JJ, Ossenkoppele GJ, Meijer CJ. ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects–a review. J Pathol. 2003;200(1):4–15May
  29. Chim CS, Ma SY, Au WY, Choy C, Lie AK, Liang R, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood. 2004;103(1):216–221Jan 1
  30. Ishida T, Inagaki H, Utsunomiya A, Takatsuka Y, Komatsu H, Iida S, et al. CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res. 2004;10(16):5494–5500Aug 15
  31. Tsuchiya T, Ohshima K, Karube K, Yamaguchi T, Suefuji H, Hamasaki M, et al. Th1, Th2, and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL. Blood. 2004;103(1):236–241Jan 1
  32. Niwa R, Shoji-Hosaka E, Sakurada M, Shinkawa T, Uchida K, Nakamura K, et al. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res. 2004;64(6):2127–2133Mar 15
  33. Suzuki R, Kagami Y, Takeuchi K, Kami M, Okamoto M, Ichinohasama R, et al. Prognostic significance of CD56 expression for ALK-positive and ALK- negative anaplastic large-cell lymphoma of T/null cell phenotype [In Process Citation]. Blood. 2000;96(9):2993–3000
  34. Schlette EJ, Medeiros LJ, Goy A, Lai R, Rassidakis GZ. Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol. 2004;22(9):1682–1688May 1
  35. ten Berge RL, Meijer CJ, Dukers DF, Kummer JA, Bladergroen BA, Vos W, et al. Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma. Blood. 2002;99(12):4540–4546Jun 15
  36. Martinez-Delgado B, Melendez B, Cuadros M, Alvarez J, Castrillo JM, Ruiz De La Parte A, et al. Expression profiling of T-cell lymphomas differentiates peripheral and lymphoblastic lymphomas and defines survival related genes. Clin Cancer Res. 2004;10(15):4971–4982Aug 1
  37. Martinez-Delgado B, Cuadros M, Honrado E, Ruiz de la Parte A, Roncador G, Alves J, et al. Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas. Leukemia. 2005;19(12):2254–2263Dec
  38. Ballester B, Gisselbrecht C, Gaulard P, Houlgatte R, Xerri L. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Annals of Oncology. 2005;16(Supp 5):124a
  39. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med. 1993;328(14):1002–1006Apr 8
  40. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rudolph C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104(3):626–633Aug 1
  41. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rube C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104(3):634–641Aug 1
  42. Escalon MP, Liu NS, Yang Y, Hess M, Walker PL, Smith TL, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma. Cancer. 2005;103(10):2091–2098May 15
  43. Klimecki WT, Futscher BW, Grogan TM, Dalton WS. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood. 1994;83(9):2451–2458May 1
  44. Vose J. The International PTCL Project Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA. International Peripheral T-Cell Lymphoma (PTCL) Clinical and Pathologic Review Project: Poor Outcome by Prognostic Indices and Lack of Efficacy with Anthracyclines. Session Type: Oral Session. Blood. 2005;106(11):811a
  45. Chim CS, Chan AC, Raymond L. Primary CD30-positive anaplastic large cell lymphoma of the lip. Oral Oncol. 1998;34(4):313–315
  46. Cheung MM, Chan JK, Lau WH, Ngan RK, Foo WW. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys. 2002;54(1):182–190Sep 1
  47. You JY, Chi KH, Yang MH, Chen CC, Ho CH, Chau WK, et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan. Ann Oncol. 2004;15(4):618–625Apr
  48. Li YX, Yao B, Jin J, Wang WH, Liu YP, Song YW, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol. 2006;24(1):181–189Jan 1
  49. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768–3785May 15
  50. Rodriguez J, Caballero MD, Gutierrez A, Marin J, Lahuerta JJ, Sureda A, et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol. 2003;14(12):1768–1775Dec
  51. Blystad AK, Enblad G, Kvaloy S, Berglund A, Delabie J, Holte H, et al. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant. 2001;27(7):711–716Apr
  52. Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia. 2006;20(9):1533–1538Sep
  53. Rodriguez J, Caballero MD, Gutierrez A, Gandarillas M, Sierra J, Lopez-Guillermo A, et al. Autologous Stem Cell Transplantation in Induction Failure Patients with Peripheral T-cell Lymphoma: The GEL/TAMO Experience. Blood. 2003;102(11):2710a
  54. Reimer P, Schertlin T, Rudiger T, Geissinger E, Roth S, Kunzmann V, et al. Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study. Hematol J. 2004;5(4):304–311
  55. Reimer P, Rudiger T, Schertlin E, Weissinger F, Einsele H, K. M-HH, et al. Autologous Stem Cell Transplantation as First-Line Therapy in Peripheral T-cell Lymphomas. A Prospective Multicenter Study. Blood 2005;106(11):2074a.
  56. Gisselbrecht C, Lepage E, Molina T, Quesnel B, Fillet G, Lederlin P, et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol. 2002;20(10):2472–2479May 15
  57. Mounier N, Gisselbrecht C, Briere J, Haioun C, Feugier P, Offner F, et al. All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Ann Oncol. 2004;15(12):1790–1797Dec
  58. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333(23):1540–1545Dec 7
  59. Kewalramani T, Zelenetz AD, Teruya-Feldstein J, Hamlin P, Yahalom J, Horwitz S, et al. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol. 2006;134(2):202–207Jul
  60. Jagasia M, Morgan D, Goodman S, Hamilton K, Kinney M, Shyr Y, et al. Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant. Leuk Lymphoma. 2004;45(11):2261–2267Nov
  61. Song KW, Mollee P, Keating A, Crump M. Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol. 2003;120(6):978–985Mar
  62. Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M, et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin’s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol. 2004;22(11):2172–2176Jun 1
  63. Sallah S, Wan JY, Nguyen NP. Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol. 2001;113(1):185–187Apr
  64. Dang NH, Pro B, Hagemeister FB, Jones D, Samuels B, Rodriguez MA, et al. Interim Analysis of a Phase II Study of Denileukin Diftitox (Ontak) for Relpased/Refractory T-cell non-Hodkin’s Lympoma. Blood. 2004;104(11):2641a
  65. Piekarz RL, Frye R, Turner M, Wright J, Allen LS, Smith S, et al. Responses and Molecular markers in patients with peripheral t-cell lymphoma treated on a phase II trial of depsipeptide, FK228. 2005;(3061a).
  66. Enblad G, Hagberg H, Erlanson M, Lundin J, MacDonald AP, Repp R, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood. 2004;103(8):2920–2924Apr 15
  67. Weidmann E, Hess G, Krause SW, Hebart H, Dreyling M, Subklewe M, et al. Combination chemo-immunotherapy using alemtuzumab, fludarabine, cyclophosphamide and doxorubicin is an effective first-line regimen in peripheral T-cell lymphoma. Blood. 2004;104(11):2640a
  68. Rodig SJ, Savage KJ, LaCasce AS, Weng AP, Harris NL, Shipp MA, et al. Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma. Am J Surg Pathol. 2007;31(1):106–112Jan
  69. Forero-Torres A, Bernstein S, Gopal A, Foss F, Leonard J, Rosenblatt J, et al. SGN-30 (anti-CD30 monoclonal antibody) is active and well tolerated in patients with refractory or recurrent systemic anaplastic large cell lymphoma. Blood. 2004;104(11):2637a
  70. Ansell SM, Byrd JC, Horwitz SM, Borchmann P, Engert A, Stair R, et al. Phase I/II Open-label dose-escalating study of MDX-060 administered weekly for 4 weeks in subjects with refractory/relapsed CD30 positive lypmphoma. Blood. 2004;104(104):2636a
  71. Passoni L, Gambacorti-Passerini C. ALK a novel lymphoma-associated tumor antigen for vaccination strategies. Leuk Lymphoma. 2003;44(10):1675–1681Oct
  72. Mounier N, Simon D, Haioun C, Gaulard P, Gisselbrecht C. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol. 2002;20(5):1426–1427Mar 1
  73. Czuczman MS, Porcu P, Johnson J, Niedzwiecki D, Canellos G, Cheson BD. CALGB 59901: Results of a phase II study of 506U78 in CTCL and PTCL. Blood. 2004;104(11):2486a
  74. Armitage JO, Vose JM, Weisenburger DD. Towards understanding the peripheral T-cell lymphomas. Ann Oncol. 2004;15(10):1447–1449Oct

PII: S0268-960X(07)00023-9

doi: 10.1016/j.blre.2007.03.001

Blood Reviews
Volume 21, Issue 4 , Pages 201-216 , July 2007

Article Tools

* Image Usage & Resolution